A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2020

Year

Solange Peters, Sarah Danson, Baktiar Hasan, Urania Dafni, Niels Reinmuth, Margarita Majem, Kurt G. Tournoy, Michael Mark, Miklos Pless, Manuel Cobo,

Journal of Thoracic Oncology

Advanced NsclcOncologySplendour TrialClinical TrialsImmune Checkpoint InhibitorPharmacotherapyStandard First-line TreatmentCancer TreatmentMedicineRadiation OncologyLung CancerHealth Sciences